

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

NCT06557265

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Nkarta, Inc.
Enrollment	96 participants

Key Eligibility Criteria

Inclusion (14)

- Age ≥18 and ≤70
- Progression despite maximal tolerated doses of renin-angiotensin system (RAS) blockade agents
- For participants taking chronic corticosteroids for management of the disease under study, the prednisone (or equivalent) dose must be ≥40 mg/day at 6 weeks prior to Screening and stable for ≥14 days before start of Screening
- Negative SARS-CoV-2 test
- For subjects on immunosuppressives or immunomodulators (other than corticosteroids), all doses must be stable for ≥4 weeks prior to Screening

... and 9 more (see full listing online)

Exclusion (30)

- eGFR < 45 ml/min/1.73 m²
- Currently requiring renal dialysis or expected to require dialysis during the study period
- Previous solid organ or hematopoietic cell transplant or planned transplant within study treatment period
- Congenital or acquired immunodeficiency resulting in severe infection or those receiving chronic immunoglobulin replacement therapy
- Liver disease or dysfunction, including cirrhosis and/or aspartate aminotransferase, alanine aminotransferase, or bilirubin ≥3 times the upper limit of normal

... and 25 more (see full listing online)

Locations (16 total)

Nkarta Investigational Site, Little Rock, Arkansas, United States
Nkarta Investigational Site, Gainesville, Florida, United States
Nkarta Investigational Site, Miami, Florida, United States

... and 13 more locations